The invention provides a 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H -Pyrazolo[3,4-b]pyridin-1-yl}benzamide is a stable crystal with excellent oral absorbability. 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyridine of the present invention Type II crystal of azolo[3,4-b]pyridin-1-yl}benzamide, characterized in that, in the powder X-ray diffraction pattern, it has a diffraction angle (2θ±0.2°) of 7.7°, 8.0° , 11.1°, 12.5°, 12.9°, 15.2°, 15.8°, 17.2°, 19.0°, 22.5°, 26.1° and 27.4° at least three or more characteristic peaks.